Advertisement
New Zealand markets closed
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NZD/USD

    0.6020
    -0.0014 (-0.23%)
     
  • NZD/EUR

    0.5586
    -0.0008 (-0.14%)
     
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • OIL

    78.94
    -0.32 (-0.40%)
     
  • GOLD

    2,372.10
    +31.80 (+1.36%)
     
  • NASDAQ

    18,132.71
    +19.25 (+0.11%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • Dow Jones

    39,444.06
    +56.30 (+0.14%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • NZD/JPY

    93.7930
    +0.0250 (+0.03%)
     

Biogen, AbbVie once-monthly MS injection wins U.S. FDA approval

May 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc.

The self-administered, under-the-skin injection, Zinbryta, is designed to treat adults with relapsing forms of the disease. (http://1.usa.gov/1TILwDg) (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)